VolitionRx Ltd. (NYSE American: VNRX) announced that its Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for “DETECSEPS,” a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, aims to transform emergency care for patients with infection and risk of sepsis progression.
Professor Djillali Annane, Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) and Scientific Director of DETECSEPS, noted that combining Volition’s Nu.Q® H3.1 biomarker with a clinical score (NEWS2) could improve early identification of sepsis and make a huge difference in terms of early detection in an emergency setting. He added that H3.1 is highly correlated with disease severity and provides excellent prognostic utility for outcomes such as organ failure and mortality. Its prognostic power at ICU admission also significantly exceeded established severity scores such as APACHE II and SOFA.
In the announcement, Volition Chief Medical Officer Dr. Andrew Retter said the company’s biomarker can deliver results within one hour on the Immunodiagnostic Systems (IDS) i10® automated analyzer, potentially enhancing emergency decision-making. Volition believes that through the earlier identification of sepsis, lives can be saved, the quality of life of survivors can be improved and importantly, that the burden on healthcare systems can be reduced.
To view the full press release, visit https://ibn.fm/2c5MW.
Volition is providing the Nu.Q® H3.1 Assay pro-bono to enable this important evaluation. For further information, visit the company’s website at www.Volition.com.
The selection of VolitionRx’s Nu.Q NETs assay for this national initiative underscores the potential of epigenetic biomarkers in critical care. If successful, DETECSEPS could establish a new standard for sepsis detection, reducing mortality and healthcare costs worldwide.
